191 related articles for article (PubMed ID: 9516912)
21. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma.
Mencoboni MP; Tredici S; Varaldo M; Queirolo G; Durand F; Rebella L; Galbusera V; Pannacciulli IM; Ghio R
Neoplasma; 2006; 53(4):333-6. PubMed ID: 16830062
[TBL] [Abstract][Full Text] [Related]
22. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.
Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC
Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
25. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
Brinkmann OA; Bruns F; Prott FJ; Hertle L
Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
[TBL] [Abstract][Full Text] [Related]
26. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M
Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825
[TBL] [Abstract][Full Text] [Related]
27. Treatment of recurrent or metastatic renal cell carcinoma.
Shah RN; Ahmad T; Eisen TG
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Choueiri TK; Dreicer R; Rini BI; Elson P; Garcia JA; Thakkar SG; Baz RC; Mekhail TM; Jinks HA; Bukowski RM
Cancer; 2006 Dec; 107(11):2609-16. PubMed ID: 17075879
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T
Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
[TBL] [Abstract][Full Text] [Related]
31. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
32. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
Seung SK; Curti BD; Crittenden M; Walker E; Coffey T; Siebert JC; Miller W; Payne R; Glenn L; Bageac A; Urba WJ
Sci Transl Med; 2012 Jun; 4(137):137ra74. PubMed ID: 22674552
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of taxol in patients with metastatic renal cell carcinoma.
Einzig AI; Gorowski E; Sasloff J; Wiernik PH
Cancer Invest; 1991; 9(2):133-6. PubMed ID: 1677827
[TBL] [Abstract][Full Text] [Related]
35. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
36. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
Schmidt H; Brown J; Mouritzen U; Selby P; Fode K; Svane IM; Cook GP; Mollerup DH; Geertsen PF
Clin Cancer Res; 2010 Nov; 16(21):5312-9. PubMed ID: 20959407
[TBL] [Abstract][Full Text] [Related]
37. [Radiochemotherapy in the treatment of metastatic renal cell carcinoma].
Strnad V; Senft M
Strahlenther Onkol; 1993 Dec; 169(12):745-7. PubMed ID: 8284748
[TBL] [Abstract][Full Text] [Related]
38. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
Diner EK; Linehan M; Walther M
Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
[TBL] [Abstract][Full Text] [Related]
39. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.
Shablak A; Sikand K; Shanks JH; Thistlethwaite F; Spencer-Shaw A; Hawkins RE
J Immunother; 2011 Jan; 34(1):107-12. PubMed ID: 21150719
[TBL] [Abstract][Full Text] [Related]
40. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
Fosså SD; Talle K
Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]